Aspirin and fracture risk: A systematic review and exploratory meta-analysis of observational studies

BMJ Open

Volumn 10, Issue 2, 2020, Pages

  Barker, A L ^a,b   Soh, Sze Ee ^a   Sanders, Kerrie M ^c,d   Pasco, Julie ^d   Khosla, Sundeep ^e   Ebeling, Peter R ^f   Ward, Stephanie A ^a   Peeters, Geeske ^g   Talevski, Jason ^c,d   Cumming, Robert G ^h   Seeman, Ego ^i,j   McNeil, John J ^a  

^a MONASH UNIVERSITY   (Australia)

^b Medibank Private   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Division of Endocrinology   (United States)

^f MONASH MEDICAL CENTRE   (Australia)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ AUSTIN HEALTH   (Australia)

^j AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

more..

Author keywords

ageing; fracture prevention; general population studies; osteoporosis; therapeutics (other)

Indexed keywords

ACETYLSALICYLIC ACID; BONE DENSITY CONSERVATION AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BONE DENSITY; CHECKLIST; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HIP; HUMAN; JOANNA BRIGG INSTITUTE CRITICAL APPRAISAL CHECKLIST; LUMBAR SPINE; META ANALYSIS; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; DRUG EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; RISK ASSESSMENT;

EID: 85080885839     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2018-026876     Document Type: Article

References (51)

1. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014;69 Suppl 1:S4-9.
2. Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses 2011;76:317-21.
3. Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006;17:1404-9.
4. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad COP, good COP? Trends Endocrinol Metab 2010;21:294-301.
5. Raisz LG, Pilbeam CC, Fall PM. Prostaglandins: mechanisms of action and regulation of production in bone. Osteoporosis Int 1993;3:136-40.
6. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359-81.
7. Pisani P, Renna MD, Conversano F, et al. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop 2016;7:171-81.
8. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
9. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180:S18-22.
10. Lloyd-Sherlock P. Population ageing in developed and developing regions: implications for health policy. Soc Sci Med 2000;51:887-95.
11. Pillay NK, Maharaj P. Population ageing in Africa. In: Aging and health in Africa. Springer, 2013: 11-51.
12. Mithal A, Bansal B, Kyer CS, et al. The Asia-Pacific regional audit-epidemiology, costs, and burden of osteoporosis in India 2013: a report of international osteoporosis foundation. Indian J Endocrinol Metab 2014;18:449-54.
13. Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the pure study data. Lancet 2016;387:61-9.
14. Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 2003;18:1795-802.
15. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. study of osteoporotic fractures Research Group. J Bone Miner Res 1996;11:29-35.
16. Bleicher K, Cumming RG, Naganathan V, et al. Lifestyle factors, medications, and disease influence bone mineral density in older men: findings from the CHAMP study. Osteoporos Int 2011;22:2421-37.
17. Hill DD, Cauley JA, Bunker CH, et al. Correlates of bone mineral density among postmenopausal women of African Caribbean ancestry: Tobago women's health study. Bone 2008;43:156-61.
18. Dobnig H, Piswanger-Solkner JC, Obermayer-Pietsch B, et al. Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 2007;92:1678-86.
19. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006;260:76-87.
20. Williams LJ, Pasco JA, Henry MJ, et al. Paracetamol (acetaminophen) use, fracture and bone mineral density. Bone 2011;48:1277-81.
21. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 2006;79:84-94.
22. Vestergaard P, Hermann P, Jensen J-EB, et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish osteoporosis prevention study (DOPS). Osteoporos Int 2012;23:1255-65.
23. Hill DD, Cauley JA, Sheu Y, et al. Correlates of bone mineral density in men of African ancestry: the Tobago bone health study. Osteoporos Int 2008;19:227-34.
24. Bonten TN, de Mutsert R, Rosendaal FR, et al. Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. Int J Cardiol 2017;244:298-302.
25. Chuang P-Y, Shen S-H, Yang T-Y, et al. Non-Steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study. BMC Musculoskelet Disord 2016;17:201.
26. Vestergaard P, Steinberg TH, Schwarz P, et al. Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 2012;160:36-40.
27. Chin K-Y. A review on the relationship between aspirin and bone health. J Osteoporos 2017;2017:3710959
28. Anello C, Fleiss JL. Exploratory or analytic meta-analysis: should we distinguish between them? J Clin Epidemiol 1995;48:109-16.
29. Martyn-St James M, Carroll S. Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone 2008;43:521-31.
30. The Joanna Briggs Institute. Joanna Briggs Institute Reviewers' Manual: 2016 Edition. Australia: The Joanna Briggs Institute, 2016.
31. Moola S, Munn Z, Sears K, et al. Conducting systematic reviews of association (etiology): the Joanna Briggs Institute's approach. Int J Evid Based Healthc 2015;13:163-9.
32. Schmidt FL, Hunter JE. Methods of meta-analysis: correcting error and bias in research findings. Sage publications, 2014.
33. Higgins JP, Green S. Cochrane Handbook for systematic reviews of interventions. The Cochrane Collaboration, 2011. www. handbook. cochrane. org
34. Deeks JJ, Higgins JP. Statistical algorithms in review manager 5. Statistical Methods Group of The Cochrane Collaboration, 2010.
35. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (moose) group. JAMA 2000;283:2008-12.
36. Jackson D, Turner R. Power analysis for random-effects meta-analysis. Res Synth Methods 2017;8:290-302.
37. Ryan R. Heterogeneity and subgroup analyses in Cochrane consumers and communication group reviews: planning the analysis at protocol stage. Available: http:// cccrg. cochrane. org [Accessed Dec 2016].
38. De Martinis M, Franceschi C, Monti D, et al. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006;80:219-27.
39. Lane NE, Bauer DC, Nevitt MC, et al. Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. the study of osteoporotic fractures Research Group. J Rheumatol 1997;24:1132-6.
40. Morton DJ, Barrett-Connor EL, Schneider DL. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho bernardo study. J Bone Miner Res 1998;13:1924-31.
41. Fang J, George MG, Gindi RM, et al. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National health interview survey, 2012). Am J Cardiol 2015;115:895-900.
42. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
43. Pasco JA, Jacka FN, Williams LJ, et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010;79:323-5.
44. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998;316:140-4.
45. Simunovic N, Sprague S, Bhandari M, et al. Methodological issues in systematic reviews and meta-analyses of observational studies in orthopaedic research. J Bone Joint Surg Am 2009;91 Suppl 3:87-94.
46. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90.
47. World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group. Diamond Pocket Books Ltd, 2003.
48. Oden A, McCloskey EV, Kanis JA, et al. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int 2015;26:2243-8.
49. Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017;390:490-9.
50. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13.
51. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005;36:1801-7.